276 related articles for article (PubMed ID: 24204708)
1. Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages.
Fregni G; Messaoudene M; Fourmentraux-Neves E; Mazouz-Dorval S; Chanal J; Maubec E; Marinho E; Scheer-Senyarich I; Cremer I; Avril MF; Caignard A
PLoS One; 2013; 8(10):e76928. PubMed ID: 24204708
[TBL] [Abstract][Full Text] [Related]
2. Effect of cytokines on NK cell activity and activating receptor expression in high-risk cutaneous melanoma patients.
Martinović KM; Milićević M; Larsen AK; Džodić R; Jurišić V; Konjević G; Vuletić A
Eur Cytokine Netw; 2019 Dec; 30(4):160-167. PubMed ID: 32096478
[TBL] [Abstract][Full Text] [Related]
3. Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients.
Konjević G; Mirjacić Martinović K; Vuletić A; Jović V; Jurisić V; Babović N; Spuzić I
Clin Exp Metastasis; 2007; 24(1):1-11. PubMed ID: 17295095
[TBL] [Abstract][Full Text] [Related]
4. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
Konjević G; Mirjačić Martinović K; Vuletić A; Babović N
Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
[TBL] [Abstract][Full Text] [Related]
5. Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts.
Nielsen N; Pascal V; Fasth AE; Sundström Y; Galsgaard ED; Ahern D; Andersen M; Baslund B; Bartels EM; Bliddal H; Feldmann M; Malmström V; Berg L; Spee P; Söderström K
Immunology; 2014 Aug; 142(4):581-93. PubMed ID: 24673109
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients.
Mirjačić Martinović KM; Babović NLj; Džodić RR; Jurišić VB; Tanić NT; Konjević GM
Melanoma Res; 2014 Aug; 24(4):295-304. PubMed ID: 24769842
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells.
Carrega P; Pezzino G; Queirolo P; Bonaccorsi I; Falco M; Vita G; Pende D; Misefari A; Moretta A; Mingari MC; Moretta L; Ferlazzo G
PLoS One; 2009 Dec; 4(12):e8132. PubMed ID: 19997637
[TBL] [Abstract][Full Text] [Related]
8. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation.
Vacca P; Martini S; Garelli V; Passalacqua G; Moretta L; Mingari MC
Eur J Immunol; 2013 Feb; 43(2):550-61. PubMed ID: 23192659
[TBL] [Abstract][Full Text] [Related]
9. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
[TBL] [Abstract][Full Text] [Related]
11. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.
Boerman GH; van Ostaijen-ten Dam MM; Kraal KC; Santos SJ; Ball LM; Lankester AC; Schilham MW; Egeler RM; van Tol MJ
Cancer Immunol Immunother; 2015 May; 64(5):573-83. PubMed ID: 25854581
[TBL] [Abstract][Full Text] [Related]
12. Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells.
Markel G; Seidman R; Besser MJ; Zabari N; Ortenberg R; Shapira R; Treves AJ; Loewenthal R; Orenstein A; Nagler A; Schachter J
PLoS One; 2009; 4(5):e5597. PubMed ID: 19440333
[TBL] [Abstract][Full Text] [Related]
13. Tumour-experienced T cells promote NK cell activity through trogocytosis of NKG2D and NKp46 ligands.
Domaica CI; Fuertes MB; Rossi LE; Girart MV; Avila DE; Rabinovich GA; Zwirner NW
EMBO Rep; 2009 Aug; 10(8):908-15. PubMed ID: 19498463
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the Expression of Surface Receptors on NK Cells and NKG2D on Immunocytes in Peripheral Blood of Patients with Nasopharyngeal Carcinoma.
Xu Y; Zhou R; Huang C; Zhang M; Li J; Zong J; Qiu S; Lin S; Chen H; Ye Y; Pan J
Asian Pac J Cancer Prev; 2018 Mar; 19(3):661-665. PubMed ID: 29580037
[TBL] [Abstract][Full Text] [Related]
15. The stage dependent changes in NK cell activity and the expression of activating and inhibitory NK cell receptors in melanoma patients.
Mirjačić Martinović K; Konjević G; Babović N; Inić M
J Surg Res; 2011 Dec; 171(2):637-49. PubMed ID: 20828749
[TBL] [Abstract][Full Text] [Related]
16. In-vitro activation of natural killer cells from regional lymph nodes of melanoma patients with interleukin-2 and interleukin-15.
Vuletić AM; Jovanić IP; Jurišić VB; Milovanović ZM; Nikolić SS; Tanić NT; Konjević GM
Melanoma Res; 2015 Feb; 25(1):22-34. PubMed ID: 25380182
[TBL] [Abstract][Full Text] [Related]
17. Phenotype and Function of Activated Natural Killer Cells From Patients With Prostate Cancer: Patient-Dependent Responses to Priming and IL-2 Activation.
Hood SP; Foulds GA; Imrie H; Reeder S; McArdle SEB; Khan M; Pockley AG
Front Immunol; 2018; 9():3169. PubMed ID: 30761160
[No Abstract] [Full Text] [Related]
18. IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.
Schilling B; Halstead ES; Schuler P; Harasymczuk M; Egan JE; Whiteside TL
Cancer Immunol Immunother; 2012 Sep; 61(9):1395-405. PubMed ID: 22270713
[TBL] [Abstract][Full Text] [Related]
19. Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy.
Fregni G; Perier A; Pittari G; Jacobelli S; Sastre X; Gervois N; Allard M; Bercovici N; Avril MF; Caignard A
Clin Cancer Res; 2011 May; 17(9):2628-37. PubMed ID: 21224372
[TBL] [Abstract][Full Text] [Related]
20. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]